Citations (62)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Rebecca Law, David Lewis, Daniel Hain, Rachel Daut, Melissa P. DelBello, Jean A. Frazier, Jeffrey H. Newcorn, Erika Nurmi, Elizabeth S. Cogan, Susanne Wagner, Holly Johnson & Jerry Lanchbury. (2022) Characterisation of seven medications approved for attention-deficit/hyperactivity disorder using in vitro models of hepatic metabolism. Xenobiotica 52:7, pages 676-686.
Read now
Read now
Ann C. Childress & Heather Chow. (2019) Amphetamine extended-release oral suspension for attention-deficit/hyperactivity disorder. Expert Review of Clinical Pharmacology 12:10, pages 965-971.
Read now
Read now
Kevin A. Ford, Gregory Ryslik, Jasleen Sodhi, Jason Halladay, Dolo Diaz, Donna Dambach & Melisa Masuda. (2015) Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications. Drug Metabolism Reviews 47:3, pages 291-319.
Read now
Read now
Anders Just Pedersen, Lars Ambach, Stefan König & Wolfgang Weinmann. (2014) Electrochemical Simulation of Phase I Metabolism for 21 Drugs Using Four Different Working Electrodes in an Automated Screening Setup with MS Detection. Bioanalysis 6:19, pages 2607-2621.
Read now
Read now
S. K. Lee, M. J. Kang, C. Jin, M. K. In, D.-H. Kim & H. H. Yoo. (2009) Flavin-containing monooxygenase 1-catalysed N,N-dimethylamphetamine N-oxidation. Xenobiotica 39:9, pages 680-686.
Read now
Read now
M. D. Lee, E. Ayanoglu & L. Gong. (2006) Drug-induced changes in P450 enzyme expression at the gene expression level: A new dimension to the analysis of drug–drug interactions. Xenobiotica 36:10-11, pages 1013-1080.
Read now
Read now
R. F. Staack, D. S. Theobald, L. D. Paul, D. Springer, T. Kraemer & H. H. Maurer. (2004) In vivo metabolism of the new designer drug 1-(4-methoxyphenyl)piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step. Xenobiotica 34:2, pages 179-192.
Read now
Read now
David G. E. Caldicott$suffix/text()$suffix/text(), Nicholas A. Edwards$suffix/text()$suffix/text(), Amanda Kruys, K. Paul Kirkbride$suffix/text()$suffix/text(), D. Noel Sims$suffix/text()$suffix/text(), Roger W. Byard$suffix/text()$suffix/text(), Michael Prior & Rod J. Irvine$suffix/text()$suffix/text(). (2003) Dancing with “Death”: P-Methoxyamphetamine Overdose and Its Acute Management. Journal of Toxicology: Clinical Toxicology 41:2, pages 143-154.
Read now
Read now
Slobodan Rendic. (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabolism Reviews 34:1-2, pages 83-448.
Read now
Read now
Articles from other publishers (53)
Zhao Wang, Tesfaye Liranso, Zulane Maldonado-Cruz, Alisa R. Kosheleff & Azmi Nasser. (2024) Impact of Viloxazine Extended-Release Capsules (Qelbree®) on Select Cytochrome P450 Enzyme Activity and Evaluation of CYP2D6 Genetic Polymorphisms on Viloxazine Pharmacokinetics. Clinical Drug Investigation.
Crossref
Crossref
Samuel Gerlach, Abdullah Al Maruf, Sarker M. Shaheen, Ryden McCloud, Madison Heintz, Laina McAusland, Paul D. Arnold & Chad A. Bousman. (2024) Effect of CYP2D6 genetic variation on patient-reported symptom improvement and side effects among children and adolescents treated with amphetamines. Pharmacogenetics and Genomics.
Crossref
Crossref
Slobodan P. Rendić, Rachel D. Crouch & F. Peter Guengerich. (2022) Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions. Archives of Toxicology 96:8, pages 2145-2246.
Crossref
Crossref
Jan Buitelaar, Sven Bölte, Daniel Brandeis, Arthur Caye, Nina Christmann, Samuele Cortese, David Coghill, Stephen V. Faraone, Barbara Franke, Markus Gleitz, Corina U. Greven, Sandra Kooij, Douglas Teixeira Leffa, Nanda Rommelse, Jeffrey H. Newcorn, Guilherme V. Polanczyk, Luis Augusto Rohde, Emily Simonoff, Mark Stein, Benedetto Vitiello, Yanki Yazgan, Michael Roesler, Manfred Doepfner & Tobias Banaschewski. (2022) Toward Precision Medicine in ADHD. Frontiers in Behavioral Neuroscience 16.
Crossref
Crossref
John S. Markowitz & Philip W. Melchert. (2022) The Pharmacokinetics and Pharmacogenomics of Psychostimulants. Child and Adolescent Psychiatric Clinics of North America 31:3, pages 393-416.
Crossref
Crossref
Moritz Losacker, Stefan W Toennes, Elizabeth B de Sousa Fernandes Perna, Johannes G Ramaekers, Joerg Roehrich & Cornelius Hess. (2021) Chiral Serum Pharmacokinetics of 4-Fluoroamphetamine after Controlled Oral Administration: Can (R)/(S)-Concentration Ratios Help in Interpreting Forensic Cases?. Journal of Analytical Toxicology 45:9, pages 985-992.
Crossref
Crossref
Shamia L. Faison, Nicholas Fry, Toyin Adewole, Oyinkansola Odebo, Zhao Wang, Vladimir MaleticAzmi Nasser. (2021) Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults. Journal of Clinical Psychopharmacology 41:2, pages 155-162.
Crossref
Crossref
Heejin Kam & Hotcherl Jeong. (2020) Pharmacogenomic Biomarkers and Their Applications in Psychiatry. Genes 11:12, pages 1445.
Crossref
Crossref
John S. MarkowitzKennerly S. Patrick. (2017) The Clinical Pharmacokinetics of Amphetamines Utilized in the Treatment of Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology 27:8, pages 678-689.
Crossref
Crossref
R. Feio-Azevedo, V.M. Costa, L.M. Ferreira, P.S. Branco, F.C. Pereira, M.L. Bastos, F. Carvalho & J.P. Capela. (2017) Toxicity of the amphetamine metabolites 4-hydroxyamphetamine and 4-hydroxynorephedrine in human dopaminergic differentiated SH-SY5Y cells. Toxicology Letters 269, pages 65-76.
Crossref
Crossref
Eun-Joo Shin, Duy-Khanh Dang, Hai-Quyen Tran, Yunsung Nam, Ji Hoon Jeong, Young Hun Lee, Kyung Tae Park, Yong Sup Lee, Choon-Gon Jang, Jau-Shyong Hong, Toshitaka Nabeshima & Hyoung-Chun Kim. (2016) PKCδ knockout mice are protected from para-methoxymethamphetamine-induced mitochondrial stress and associated neurotoxicity in the striatum of mice. Neurochemistry International 100, pages 146-158.
Crossref
Crossref
James C. Ermer, Michael Pennick & Glen Frick. (2016) Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy. Clinical Drug Investigation 36:5, pages 341-356.
Crossref
Crossref
Yitong Liu & Michael F. Santillo. (2015) Cytochrome P450 2D6 and 3A4 enzyme inhibition by amine stimulants in dietary supplements. Drug Testing and Analysis 8:3-4, pages 307-310.
Crossref
Crossref
Foon Yin Lai, Claudio Erratico, Juliet Kinyua, Jochen F. Mueller, Adrian Covaci & Alexander L.N. van Nuijs. (2015) Liquid chromatography-quadrupole time-of-flight mass spectrometry for screening in vitro drug metabolites in humans: investigation on seven phenethylamine-based designer drugs. Journal of Pharmaceutical and Biomedical Analysis 114, pages 355-375.
Crossref
Crossref
Jessica K. Roberts, Sarah F. Cook, Chris Stockmann, Douglas E. Rollins, Diana G. Wilkins & Catherine M. T. Sherwin. (2015) A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults. Clinical Drug Investigation 35:10, pages 633-643.
Crossref
Crossref
James Ermer, Mary Corcoran & Patrick Martin. (2015) Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. Drugs in R&D 15:2, pages 175-185.
Crossref
Crossref
Przemyslaw Mielczarek, Hana Raoof, Jolanta H. Kotlinska, Piotr Stefanowicz, Zbigniew Szewczuk, Piotr Suder & Jerzy Silberring. (2014) Electrochemical Simulation of Cocaine Metabolism—A Step toward Predictive Toxicology for Drugs of Abuse. European Journal of Mass Spectrometry 20:4, pages 279-285.
Crossref
Crossref
Sangkyu Lee, Hye Hyun Yoo, Moon Kyo In, Changbae Jin & Dong Hyun Kim. (2013) Stereoselectivity in the cytochrome P450-dependent N-demethylation and flavin monooxygenase-dependent N-oxidation of N,N-dimethylamphetamine. Archives of Pharmacal Research 36:11, pages 1385-1391.
Crossref
Crossref
Eric Sands. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
3
.
P Blanckaert, JGC van Amsterdam, TM Brunt, JDJ van den Berg, F Van Durme, K Maudens & JCH van Bussel. (2013) 4-Methyl-amphetamine: a health threat for recreational amphetamine users. Journal of Psychopharmacology 27:9, pages 817-822.
Crossref
Crossref
Benno Roesch, Mary E. Corcoran, Jennifer Fetterolf, Mary Haffey, Patrick Martin, Peter Preston, Jaideep Purkayastha, Phillip Wang & James Ermer. (2013) Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate. Drugs in R&D 13:2, pages 119-128.
Crossref
Crossref
James Ermer, Mary B. Haffey, Cynthia Richards, Kenneth Lasseter, Benno Roesch, Jaideep Purkayastha, Mary Corcoran, Bree Harlin & Patrick Martin. (2013) An Open-Label Investigation of the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Venlafaxine Extended-Release, Administered Alone and in Combination, in Healthy Adults. Clinical Drug Investigation 33:4, pages 243-254.
Crossref
Crossref
Márcia Carvalho, Helena Carmo, Vera Marisa Costa, João Paulo Capela, Helena Pontes, Fernando Remião, Félix Carvalho & Maria de Lourdes Bastos. (2012) Toxicity of amphetamines: an update. Archives of Toxicology 86:8, pages 1167-1231.
Crossref
Crossref
Ann C. Childress. (2012) Guanfacine Extended Release as Adjunctive Therapy to Psychostimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. Advances in Therapy 29:5, pages 385-400.
Crossref
Crossref
Markus R. Meyer & Hans H. Maurer. 2012. Metabolism of Drugs and Other Xenobiotics. Metabolism of Drugs and Other Xenobiotics
429
463
.
Pierre Baumann & Christoph Hiemke. 2012. Metabolism of Drugs and Other Xenobiotics. Metabolism of Drugs and Other Xenobiotics
301
329
.
Donald G. BarcelouxBrandon Wills & Timothy Erickson. 2012. Medical Toxicology of Drug Abuse. Medical Toxicology of Drug Abuse
156
192
.
Loralie Langman, Laura Bechtel & Christopher P. Holstege. 2012. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics
1109
1188
.
Osama S. El-Tawil, Ali H. Abou-Hadeed, Mohamed F. EL-Bab & Abeir A. Shalaby. (2011) d-Amphetamine-induced cytotoxicity and oxidative stress in isolated rat hepatocytes. Pathophysiology 18:4, pages 279-285.
Crossref
Crossref
Tomáš Páleníček, Marie Balíková, Miroslava Rohanová, Tomáš Novák, Jiří Horáček, Michaela Fujáková & Cyril Höschl. (2011) Behavioral, hyperthermic and pharmacokinetic profile of para-methoxymethamphetamine (PMMA) in rats. Pharmacology Biochemistry and Behavior 98:1, pages 130-139.
Crossref
Crossref
Mark K Greenwald, Leslie H Lundahl & Caren L Steinmiller. (2010) Sustained Release d-Amphetamine Reduces Cocaine but not ‘Speedball’-Seeking in Buprenorphine-Maintained Volunteers: A Test of Dual-Agonist Pharmacotherapy for Cocaine/Heroin Polydrug Abusers. Neuropsychopharmacology 35:13, pages 2624-2637.
Crossref
Crossref
Brandy Hood & Michael J. Nowicki. (2010) Eosinophilic Hepatitis in an Adolescent During Lisdexamfetamine Dimesylate Treatment for ADHD. Pediatrics 125:6, pages e1510-e1513.
Crossref
Crossref
Rayomand J. Unwalla, Jason B. Cross, Sumeet Salaniwal, Adam D. Shilling, Louis Leung, John Kao & Christine Humblet. (2010) Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism. Journal of Computer-Aided Molecular Design 24:3, pages 237-256.
Crossref
Crossref
Vessela Vitcheva, Magdalena Kondeva-Burdina & Mitka Mitcheva. (2009) D-Amphetamine Toxicity in Freshly Isolated Rat Hepatocytes: A Possible Role of CYP3A. Archives of Industrial Hygiene and Toxicology 60:2, pages 139-145.
Crossref
Crossref
Sang Kyu Lee, Yoon Kim, SungIll Suh, Yong Jun Suh, Moon Kyo In, Dong-Hyun Kim, Changbae Jin & Hye Hyun Yoo. (2009) Detox agents do not affect the pharmacokinetics of methamphetamine in the rat. Forensic Science International 186:1-3, pages e21-e24.
Crossref
Crossref
Britta Bonn, Collen M. Masimirembwa, Yasmin Aristei & Ismael Zamora. (2008)
The Molecular Basis of CYP2D6-Mediated
N
-Dealkylation: Balance between Metabolic Clearance Routes and Enzyme Inhibition
. Drug Metabolism and Disposition 36:11, pages 2199-2210.
Crossref
Crossref
Ulrich M. Zanger, Miia Turpeinen, Kathrin Klein & Matthias Schwab. (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and Bioanalytical Chemistry 392:6, pages 1093-1108.
Crossref
Crossref
Kei Zaitsu, Munehiro Katagi, Tooru Kamata, Hiroe Kamata, Noriaki Shima, Hitoshi Tsuchihashi, Takeshi Hayashi, Hisanaga Kuroki & Ryoji Matoba. (2008) Determination of a newly encountered designer drug “p-methoxyethylamphetamine” and its metabolites in human urine and blood. Forensic Science International 177:1, pages 77-84.
Crossref
Crossref
Richard A. Glennon, Richard Young, Małgorzata Dukat, Jean Chang-Fong & Mohamed El-Zahabi. (2007) N-Methyl-1-(4-methoxyphenyl)-2-aminopropane (PMMA) and N-Methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) produce non-identical discriminative stimuli in rats. Pharmacology Biochemistry and Behavior 86:3, pages 477-484.
Crossref
Crossref
Félix Carvalho, Maria Elisa Soares, Eduarda Fernandes, Fernando Remião, Márcia Carvalho, José Alberto Duarte, Ricardo Pires-das-Neves, Maria de Lourdes Pereira & Maria de Lourdes Bastos. (2007) Repeated Administration of d-Amphetamine Results in a Time-dependent and Dose-independent Sustained Increase in Urinary Excretion of p-Hydroxyamphetamine in Mice. Journal of Health Science 53:4, pages 371-377.
Crossref
Crossref
Suma Krishnan & Scott Moncrief. (2007) An Evaluation of the Cytochrome P450 Inhibition Potential of Lisdexamfetamine in Human Liver Microsomes. Drug Metabolism and Disposition 35:1, pages 180-184.
Crossref
Crossref
Helena Carmo, Marc Brulport, Matthias Hermes, Franz Oesch, Douwe de Boer, Fernando Remião, Félix Carvalho, Michael R. Schön, Niels Krebsfaenger, Johannes Doehmer, Maria de Lourdes Bastos & Jan G. Hengstler. (2007) CYP2D6 increases toxicity of the designer drug 4-methylthioamphetamine (4-MTA). Toxicology 229:3, pages 236-244.
Crossref
Crossref
K. A. Rittenbach & G. B. Baker. 2007. Handbook of Neurochemistry and Molecular Neurobiology. Handbook of Neurochemistry and Molecular Neurobiology
1
16
.
Helena Carmo, Jan G. Hengstler, Douwe de Boer, Michael Ringel, Fernando Remião, Félix Carvalho, Eduarda Fernandes, Lesseps A. dos Reys, Franz Oesch & Maria de Lourdes Bastos. (2005) Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human. Toxicology 206:1, pages 75-89.
Crossref
Crossref
H CARMO, D BOER, F REMIAO, F CARVALHO, L REYS & M BASTOS. (2004) Metabolism of the designer drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in mice, after acute administration. Journal of Chromatography B 811:2, pages 143-152.
Crossref
Crossref
Thomas Kraemer, Thomas Pflugmann, Michael Bossmann, Nicole M Kneller, Frank T Peters, Liane D Paul, Dietmar Springer, Roland F Staack & Hans H Maurer. (2004) Fenproporex N-dealkylation to amphetamine—enantioselective in vitro studies in human liver microsomes as well as enantioselective in vivo studies in Wistar and Dark Agouti rats. Biochemical Pharmacology 68:5, pages 947-957.
Crossref
Crossref
Karl Hofbauer, Ulrich Keller & Olivier BossStephan Krähenbühl. 2004. Pharmacotherapy of Obesity. Pharmacotherapy of Obesity
285
296
.
Roland F. Staack, Denis S. Theobald, Liane D. Paul, Dietmar Springer, Thomas Kraemer & Hans H. Maurer. (2004)
IDENTIFICATION OF HUMAN CYTOCHROME P450 2D6 AS MAJOR ENZYME INVOLVED IN THE
O
-DEMETHYLATION OF THE DESIGNER DRUG
P
-METHOXYMETHAMPHETAMINE
. Drug Metabolism and Disposition 32:4, pages 379-381.
Crossref
Crossref
Rafael de la Torre, Mag?? Farr??M??nica Navarro, Roberta Pacifici, Piergiorgio Zuccaro & Simona Pichini. (2004) Clinical Pharmacokinetics of Amfetamine and Related Substances. Clinical Pharmacokinetics 43:3, pages 157-185.
Crossref
Crossref
Amit S. Kalgutkar, Sue Zhou, Odette A. Fahmi & Timothy J. Taylor. (2003)
Influence of Lipophilicity on the Interactions of
N-
Alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and Their Positively Charged
N-
Alkyl-4-phenylpyridinium Metabolites with Cytochrome P450 2D6
. Drug Metabolism and Disposition 31:5, pages 596-605.
Crossref
Crossref
Eleni Aklillu, Karin Herrlin, Lars L Gustafsson, Leif Bertilsson & Magnus Ingelman-Sundberg. (2002) Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 12:5, pages 375-383.
Crossref
Crossref
Thomas Kraemer & Hans H. Maurer. (2002) Toxicokinetics of Amphetamines: Metabolism and Toxicokinetic Data of Designer Drugs, Amphetamine, Methamphetamine, and Their N-Alkyl Derivatives. Therapeutic Drug Monitoring 24:2, pages 277-289.
Crossref
Crossref
John S. Markowitz & Kennerly S. Patrick. (2001) Pharmacokinetic and Pharmacodynamic Drug Interactions in the Treatment of Attention-Deficit Hyperactivity Disorder. Clinical Pharmacokinetics 40:10, pages 753-772.
Crossref
Crossref